## EXHIBIT 449

UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF OHIO

EASTERN DIVISION

- - -

IN RE: NATIONAL

PRESCRIPTION : MDL No. 2804

OPIATE LITIGATION :

\_\_\_ : Case No. : 1:17-MD-2804

THIS DOCUMENT RELATES

TO ALL CASES : Hon. Dan A. Polster

- - -

Monday, January 7, 2019

HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

- - -

Videotaped deposition of TOM NAMETH, held at the offices of Cavitch, Familo & Durkin,
1300 East Ninth Street, Cleveland, Ohio, commencing at
9:03 a.m., on the above date, before Carol A. Kirk,
Registered Merit Reporter and Notary Public.

- - -

GOLKOW LITIGATION SERVICES 877.370.3377 ph | 917.591.5672 fax deps@golkow.com

## Case: 1:17-md-02804-DAP Doc #: 1967-25 Filed: 07/23/19 3 of 3. PageID #: 176335 Highly Confidential - Subject to Further Confidentiality Review

|    | Page 11  |          | Page 112   |
|----|--|----------|--|
| 1  | the IT side.   | 1        | Q. Okay. And so let's talk about   |
| 2  | Q. Okay. Was there ever any  | 2        | this a little more.  |
| 3  | discussion about whether a report like that                                      | 3        | Did that system have to prevent  |
| 4  | would be useful in detecting and halting   | 4        | diversion or simply identify it and respond to   |
| 5  | diversion in its tracks?   | 5        | it after the fact; do you know?  |
| 6  | A. No.   | 6        | A. Well, it would prevent diversion  |
| 7  | Q. Okay. All right. We're going to   | 7        | as far as looking at the system and knowing  |
| 8  | turn to what Mr. Knoll is going to mark as                                       | 8        | whether it was diversion or not. If it wasn't,   |
| 9  | Exhibit 3.   | 9        | then it wouldn't be diversion.   |
| 10 | MR. MULLIGAN: Actually, you know   | 10       | Q. Your report would only allow you  |
| 11 | what, before we get there, Jon, I've got   | 11       | to identify it had already happened  |
| 12 | a couple questions. So mark it and   | 12       | A. Yes.  |
| 13 | we'll just   | 13       | Q which would then potentially   |
| 14 | BY MR. MULLIGAN:   | 14       | enable you to try and stop it in the future,   |
| 15 | Q. You'd agree, Mr. Nameth, that   | 15       | right?   |
| 16 | patient and customer safety are DDM's first                                      | 16       | A. Well, but by following up,  |
| 17 | priority?  | 17       | wouldn't we be actually looking at that  |
| 18 | A. I would agree.  | 18       | particular issue?  |
| 19 | Q. Okay. Along with maybe staying in   | 19       | Q. Well, you tell me.  |
| 20 | business?  | 20       | A. Yes. I mean, we would look at a   |
| 21 | A. Well  | 21       | particular issue and follow up with a written  |
| 22 | Q. Is that fair?   | 22       | report and find out whether it was diversion or  |
| 23 | A. I would say that we have a  | 23       | not. So  |
| 24 | responsibility to our customers' patients, yes.                                  | 24       | Q. But you'd agree that that's   |
|    | Page 11:   |          | Page 113   |
| 1  | Q. Okay. Do you agree that DDM as a  |          | identifying that diversion has already happened,   |
| 2  | handler of controlled substance also has an                                      | 2        | so it's not actually preventing diversion,   |
| 3  | obligation to the general public to prevent                                      | 3        | agree?   |
| 4  | diversion of opioids?  A. Yes.   | 4        | A. What it is, it's in my opinion,   |
| 5  |  | 5        | it's preventing diversion by looking at the system and determining whether there's diversion |
| 7  | Q. Okay. And would you agree that DDM was legally required to implement a system | 7        | or not. What you're asking is, are you going to  |
| 8  | of effective controls to prevent diversion?                                      | 8        | stop an order before it went out the door?   |
| 9  | A. We were required to have a system.  | 9        | Q. Correct.  |
| 10 | Q. Okay. To prevent diversion,   | 10       | A. No, it did not.   |
| 11 | correct?   | 11       | Q. Okay. So it potentially was a   |
| 12 | A. Yes.  | 12       | tool that could put you on notice that diversion   |
| 13 | Q. Okay. And not to respond to it,   | 13       | had already occurred and then give you the   |
| 14 | right?   | 14       | option to try and stem it or prevent it in the   |
| 15 | A. Well, now, you're getting into  | 15       | future, correct?   |
| 16 | we felt our system was adequate for what we                                      | 16       | A. Yes.  |
| 17 | needed to be done.   | 17       | Q. Okay. And you guys never  |
| 18 | Q. Okay. And what you needed to be   | 18       | identified a suspicious order, right?  |
| 19 | done is defined by the Controlled Substances                                     | 19       | A. Right.  |
| 20 | Act, right?  | 20       | Q. And so you never determined that  |
| 21 | A. Yes.  | 21       | any diversion was taking place regarding   |
| 22 | Q. And you're a pharmacist, and you  | 22       | suspicious orders, right?  |
|    |  |          |  |
| 23 | know that, right?  | 23       | A. Right.  |
|    |  | 23<br>24 | <ul><li>A. Right.</li><li>Q. And so, therefore, you guys didn't</li></ul>                    |